Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α

@inproceedings{Tsuboi2014ClinicalCO,
  title={Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α},
  author={Kazuya Tsuboi and Hiroshi Yamamoto},
  booktitle={Genetics in Medicine},
  year={2014}
}
Background:Between 2009 and 2012, there was a worldwide shortage of agalsidase-β for the treatment of Fabry disease. Therefore, alternative treatments were needed, including switching to a different enzyme-replacement therapy.Purpose:This is an ongoing observational study assessing the effects of switching from agalsidase-β (1.0 mg/kg every other week) to agalsidase-α (0.2 mg/kg every other week) in 11 patients with Fabry disease.Methods:Clinical data were collected for 5 years—2 years before… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients

  • Spinelli L Pisani A, Visciano
  • Orphanet J Rare Dis
  • 2011

Similar Papers

Loading similar papers…